medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Number 4

<< Back Next >>

Rev Mex Neuroci 2019; 20 (4)

Factors associated with Parkinson’s disease in patients from the Comarca Lagunera, Mexico

Ventura-Chávez R, Reyna-Gil AI, García S

Language: Spanish
References: 47
Page: 174-179
PDF size: 115.46 Kb.


ABSTRACT

Introduction: Parkinson’s disease (PD) is a progressive, incapacitating and incurable neurodegenerative disease; in 90% of cases its etiology is polygenic and multifactorial. Comarca Lagunera is the ninth most populated area of Mexico, located in the center-north; its concentrations of arsenic, cadmium and lead exceed in 1-3 orders of magnitude acceptable levels. Objective: To evaluate the association of environmental factors with the development of PD in this region. Materials and Methods: Patients and controls were more of 18 years old, they agreed to participate with the signature of the informed consent; they were natives and residents of Lagunera region; PD diagnosis was made according Diagnostic Criteria of the Brain Bank of the United Kingdom; controls were healthy people without history of neurological disease. All of them underwent neurological evaluation. Results: 204 people were included: 60 persons with PD diagnoses and 144 controls; consumption of tobacco, coffee and tea were associated to negative effect to develop PD, while rural housing, source of water consumption, and the exposition to pesticides and lead were not associated to PD. Conclusions: In accordance with other studies, smoking, consumption of coffee and tea were protective factors for the development of PE, while consumption water well, exposure to pesticides and/or lead, and rural housing were not associated to PD; so, their presumed participation as “triggers” of the disease remains controversial.


REFERENCES

  1. Varanese S, Birnbaum Z, Rossi R, Di Rocco A. Treatment of advanced Parkinson´s Disease. Parkinsons Dis. 7;2010:480260. doi: 10.4061/ 2010/480260.

  2. Diagnóstico y tratamiento de la Enfermedad de Parkinson inicial y avanzada en el tercer nivel de atención. Secretaría de Salud [Internet]. México: CENETEC; 2010 [fecha de consulta: 5 de junio de 2018.] Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 153_GPC_PARKINSON/SSA_153_08_GRR_Parkinson.pdf

  3. Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson’s disease and Parkinsonism. Expert Rev Neurother. 2007;7:657-66.

  4. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution. Multiple clues to a complex disorder. Neurology. 2007; 69:2093-104.

  5. Arriaga-Cabrera L, Espinoza-Rodríguez JM, Aguilar-Zúñiga C, Martínez- Romero E, Gómez-Mendoza L, Loa-Loza E (coord.). Regiones terrestres prioritarias de México [Internet]. México: Comisión nacional para el conocimiento y uso de la biodiversidad; 2000 [fecha de consulta: 5 de junio de 2018]. Disponible en: http://bioteca.biodiversidad.gob.mx/janium/ Documentos/1036.pdf

  6. Cervantes MC, Franco González RAM. Diagnóstico ambiental de la Comarca Lagunera [Internet]. México: Facultad de Filosofía y letras, UNAM; 2010 [fecha de consulta: 5 de junio de 2018]. Disponible en: http://docplayer. es/28258983-Diagnostico-ambiental-de-la-comarca-lagunera.html

  7. Flores Hernández A, Hernández F, Orona Castillo MI. Programa Integral de Transferencia de Tecnología y Servicios Agropecuarios Laguna (PITTSAL). Rev Mex Agroneg. 2004;VIII(14):252-8.

  8. Santamaría J, Reta Sánchez D, Chávez González JF, Cueto Wong GA, Romero Paredes JI. Caracterización del medio físico en relación a cultivos forrajeros alternativos para la Comarca Lagunera. Libro Técnico Núm. 2. INIFAP-CIRNOC-CELALA. 2006;2-240-

  9. García Vargas GG, Rubio Andrade M, Rosales González MG, Goytia Acevedo R, García Arenas G, Candelas Rangel JL, et al. Contaminación por metales en suelos de la ciudad de Torreón Coahuila. México. Rev Chapingo ser zonas áridas. 2007;6:165-8.

  10. Varanese S, Birnbaum Z, Rossi R, Di Rocco A. Treatment of advanced Parkinson’s disease. Parkinsons Dis. 2011;2010:480260.

  11. Allam MF, del Castillo AS, Navajas RFC. Factores de riesgo de la enfermedad de Parkinson. Rev Neurol. 2003;36:749-55.

  12. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez- Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5.

  13. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta- analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276-84.

  14. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurolo. 2001;50:56-63.

  15. Barranco Quintana JL, Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease and tea: a quantitative review. J Am Coll Nutr. 2009;28:1‑6.

  16. Kenborg L, Rugbjerg K, Lee P-C, Ravnskjær L, Christensen J, Ritz B, et al. Lassen head injury and risk for Parkinson disease: Results from a Danish case-control study. Neurology. 2015;84:1098-103.

  17. Bettiol SS, Rose TC, Hughes CJ, Smith LA. Alcohol consumption and Parkinson’s disease risk: A review of recent findings. J Parkinsons Dis. 2015;5:425-42.

  18. Fukushima W, Miyake Y, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, et al. Alcohol drinking and risk of Parkinson’s disease: a case-control study in Japan. BMC Neurol. 2010;10:111.

  19. Willis AW, Evanoff BA, Lian M, Galarza A, Wegrzyn A, Schootman M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol. 2010;172:1357-63.

  20. Guilarte TM. Manganese and Parkinson’s disease: A critical review and new findings. Environ Health Perspect. 2010;118:1071-80.

  21. Cholanians AB, Phan AV, Ditzel EJ, Camenisch TD, Lau SS, Monks TK. From the cover: Arsenic induces accumulation of α-synuclein: Implications for synucleinopathies and neurodegeneration. Oxicol Sci. 2016;153:271-81.

  22. Tyler CR, Allan AM. The effects of arsenic exposure on neurological and cognitive dysfunction in human and rodent studies: A review. Curr Environ Health Rep. 2014;1:132-47.

  23. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4:362-55.

  24. de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology. 2006;67:315-318.

  25. Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL. Risk of Parkinson’s disease after tamoxifen treatment. BMC Neurol. 2010;12:10:23.

  26. Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord. 1995;10:250-6.

  27. Castro de EsparzaML. Presencia de arsénico en el agua de bebida en América Latina y su efecto en la salud pública [Internet]. International Congress, Ciudad de México, junio de 2006 [fecha de consulta: 6 de junio de 2018]. Disponible en: http://www.bvsde.ops-oms.org/bvsacd/ cd51/arsenico-agua.pd

  28. Ochoa Reyes J, Vidal Lozano A, Lerma Santana A, Gómez Reza L, Reta Sánchez A, Fernández Escajeda D, et al. Arsenicismo subagudo y crónica en una población rural. Dermatologia Rev Mex. 2009;53:63-9.

  29. T Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-52.

  30. Martinez-Martin P, Prieto João Forjaz M. Longitudinal metric properties of disability rating scales for Parkinson’s disease value in health. Value Health. 2006;9(6):386-93.

  31. Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188:1157-65.

  32. Rodríguez-Violante M, Villar-Velarde A, Valencia-Ramos C, Cervantes- Arriaga A. Características epidemiológicas de pacientes con enfermedad de Parkinson de un hospital de referencia en México. Neurocien (Mex) INNN. 2011;16:64-8.

  33. Muangpaisan W, Mathews A, Hori H, Seidel D. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J Med Assoc Thai. 2011;94:749-55.

  34. Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Transl Neurodegener. 2017;6:18.

  35. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol. 2002;53:590-605.

  36. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol. 2007; 74:1235-46.

  37. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson’s disease. Mov Disord. 2012;27:947-57.

  38. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson´s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257-72.

  39. Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis. 2010;20(Suppl 1):S221-38.

  40. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 2006;29:647-54.

  41. Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, et al. Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson’s disease. Review Neurobiol Dis. 2014;67:191-202.

  42. Prediger RD. Effects of caffeine in Parkinson’s disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 2010;20(Suppl 1):S205-220.

  43. Feng-Jiao Li, Hong-Fang Ji, Liang She. A meta-analysis of tea drinking and risk of Parkinson’s disease. Neurobiol Dis. 2014;67:191-202.

  44. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int. 2014; 14:430-9.

  45. Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect. 2005: 113:1234-8.

  46. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26:(Suppl 1):S1-58.

  47. Breckenridge CB, Berry C, Chang ET, Sielken RL Jr, Mandel JS. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: Systematic review and meta-analysis. PLoS ONE 11:e0151841.




2020     |     www.medigraphic.com